Allelic loss of HLA class I facilitates evasion from immune surveillance in cervical intraepithelial neoplasia

HLA. 2024 Jun;103(6):e15509. doi: 10.1111/tan.15509.

Abstract

Loss of heterozygosity (LOH) has been reported to occur in HLA regions in cervical intraepithelial neoplasia (CIN) and cervical cancer. However, the details of how this is related to the progression of CIN have been unclear. In this study, we examined the human papillomavirus (HPV) antigen-presenting capacity of people with CIN and the significance of LOH of HLA class I in the progression of CIN. It was shown that differences in antigen-presenting capacity among each case depended on HLA types, not HPV genotypes. Focusing on the HLA type, there was a positive correlation between antigen-presenting capacity against HPV and the frequency of allelic loss. Furthermore, the lost HLA-B alleles had a higher HPV antigen-presenting capacity than intact alleles. In addition, frequency of LOH of HLA class I was significantly higher in advanced CIN (CIN2-3) than in cervicitis or early-stage CIN (CIN1): around half of CIN2-3 had LOH of any HLA class I. Moreover, the antigen-presenting capacity against E5, which is the HPV proteins that facilitate viral escape from this immune surveillance by suppressing HLA class I expression, had the most significant impact on the LOH in HLA-B. This study suggests that HPV evades immune surveillance mechanisms when host cells lose the capacity for antigen presentation by HLA class I molecules, resulting in long-term infection and progression to advanced lesions.

Keywords: HLA class I; cervical cancer; cervical intraepithelial neoplasm; human papillomavirus; loss of heterozygosity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alleles
  • Antigen Presentation / immunology
  • Female
  • Genotype
  • Histocompatibility Antigens Class I* / genetics
  • Histocompatibility Antigens Class I* / immunology
  • Humans
  • Immunologic Surveillance
  • Loss of Heterozygosity*
  • Middle Aged
  • Papillomaviridae / immunology
  • Papillomavirus Infections* / genetics
  • Papillomavirus Infections* / immunology
  • Uterine Cervical Dysplasia* / genetics
  • Uterine Cervical Dysplasia* / immunology
  • Uterine Cervical Dysplasia* / pathology
  • Uterine Cervical Dysplasia* / virology
  • Uterine Cervical Neoplasms* / genetics
  • Uterine Cervical Neoplasms* / immunology

Substances

  • Histocompatibility Antigens Class I